ANTEPAR Drug Patent Profile
✉ Email this page to a colleague
When do Antepar patents expire, and when can generic versions of Antepar launch?
Antepar is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in ANTEPAR is piperazine citrate. There are eighteen drug master file entries for this compound. Additional details are available on the piperazine citrate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ANTEPAR?
- What are the global sales for ANTEPAR?
- What is Average Wholesale Price for ANTEPAR?
Summary for ANTEPAR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 56 |
| DailyMed Link: | ANTEPAR at DailyMed |
US Patents and Regulatory Information for ANTEPAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | ANTEPAR | piperazine citrate | SYRUP;ORAL | 009102-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Glaxosmithkline | ANTEPAR | piperazine citrate | TABLET;ORAL | 009102-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
